The role of antigen-specific and non-specific immunotherapy in the treatment of cancer

Arta M Monjazeb, Hui Hua Hsiao, Gail D. Sckisel, William J Murphy

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Immunotherapy in the treatment of cancer is increasing, particularly with the recent FDA approval of sipuleucel-T and ipilimumab. The efficacy of anti-tumor immunotherapies has been modest compared to their theoretical and pre-clinical promise. This review evaluates the promise and pitfalls of immunotherapy and highlight some of the obstacles to improving anti-tumor immunotherapy: the need for technical refinement of therapies, the need for an increased understanding of how best to combine therapies with traditional cytotoxic therapies, the inability of patients to mount an effective immune response either due to disease burden or tumor induced immune suppression, the significant toxicities associated with many immunotherapies, and the lack of strongly immunogenic antigens required by many therapies. Further, antigen-non-specific immunotherapies, including cytokines such as interleukins and interferons, immuno-stimulatory agents such as CpG oligonucleotides, or BCG, antibodies targeted against receptors such as the agonistic CD40 or inhibitory CTLA-4 antibodies, and enzyme inhibitors such as those targeting cyclo-oxygenase or indolamine-2,3-dioxygenase are discussed. In addition, potential mechanisms of these therapies such as direct anti-tumor effects, reversal of immune suppression, activation of innate immunity, and antigen-non-specific T-cell activation are reviewed. We also appraise the potential of these antigen-non-specific therapies to overcome some of the previously described pitfalls of immunotherapy. Lastly, we discuss a recent series of studies from our laboratory demonstrating the importance of antigen-non-specific 'bystander activation' of memory T-lymphocytes by immunomodulatory therapies such as interleukin-2 and the antigen-non-specific anti-tumor effects of these cells.

Original languageEnglish (US)
Pages (from-to)248-258
Number of pages11
JournalJournal of Immunotoxicology
Volume9
Issue number3
DOIs
StatePublished - Jul 2012

Fingerprint

Immunotherapy
Tumors
Antigens
Neoplasms
T-cells
Chemical activation
Therapeutics
Indoleamine-Pyrrole 2,3,-Dioxygenase
Antibodies
T-Lymphocytes
Interleukins
Enzyme Inhibitors
Prostaglandin-Endoperoxide Synthases
Immunomodulation
Oligonucleotides
Interferons
Interleukin-2
Mycobacterium bovis
Toxicity
Tumor Burden

Keywords

  • Bystander T-cells
  • Cancer
  • Cancer vaccine
  • Immunotherapy
  • Tumor immunology

ASJC Scopus subject areas

  • Toxicology
  • Immunology

Cite this

The role of antigen-specific and non-specific immunotherapy in the treatment of cancer. / Monjazeb, Arta M; Hsiao, Hui Hua; Sckisel, Gail D.; Murphy, William J.

In: Journal of Immunotoxicology, Vol. 9, No. 3, 07.2012, p. 248-258.

Research output: Contribution to journalArticle

@article{c6deaf791a7b47b4bee22804d0650a5f,
title = "The role of antigen-specific and non-specific immunotherapy in the treatment of cancer",
abstract = "Immunotherapy in the treatment of cancer is increasing, particularly with the recent FDA approval of sipuleucel-T and ipilimumab. The efficacy of anti-tumor immunotherapies has been modest compared to their theoretical and pre-clinical promise. This review evaluates the promise and pitfalls of immunotherapy and highlight some of the obstacles to improving anti-tumor immunotherapy: the need for technical refinement of therapies, the need for an increased understanding of how best to combine therapies with traditional cytotoxic therapies, the inability of patients to mount an effective immune response either due to disease burden or tumor induced immune suppression, the significant toxicities associated with many immunotherapies, and the lack of strongly immunogenic antigens required by many therapies. Further, antigen-non-specific immunotherapies, including cytokines such as interleukins and interferons, immuno-stimulatory agents such as CpG oligonucleotides, or BCG, antibodies targeted against receptors such as the agonistic CD40 or inhibitory CTLA-4 antibodies, and enzyme inhibitors such as those targeting cyclo-oxygenase or indolamine-2,3-dioxygenase are discussed. In addition, potential mechanisms of these therapies such as direct anti-tumor effects, reversal of immune suppression, activation of innate immunity, and antigen-non-specific T-cell activation are reviewed. We also appraise the potential of these antigen-non-specific therapies to overcome some of the previously described pitfalls of immunotherapy. Lastly, we discuss a recent series of studies from our laboratory demonstrating the importance of antigen-non-specific 'bystander activation' of memory T-lymphocytes by immunomodulatory therapies such as interleukin-2 and the antigen-non-specific anti-tumor effects of these cells.",
keywords = "Bystander T-cells, Cancer, Cancer vaccine, Immunotherapy, Tumor immunology",
author = "Monjazeb, {Arta M} and Hsiao, {Hui Hua} and Sckisel, {Gail D.} and Murphy, {William J}",
year = "2012",
month = "7",
doi = "10.3109/1547691X.2012.685527",
language = "English (US)",
volume = "9",
pages = "248--258",
journal = "Journal of Immunotoxicology",
issn = "1547-691X",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - The role of antigen-specific and non-specific immunotherapy in the treatment of cancer

AU - Monjazeb, Arta M

AU - Hsiao, Hui Hua

AU - Sckisel, Gail D.

AU - Murphy, William J

PY - 2012/7

Y1 - 2012/7

N2 - Immunotherapy in the treatment of cancer is increasing, particularly with the recent FDA approval of sipuleucel-T and ipilimumab. The efficacy of anti-tumor immunotherapies has been modest compared to their theoretical and pre-clinical promise. This review evaluates the promise and pitfalls of immunotherapy and highlight some of the obstacles to improving anti-tumor immunotherapy: the need for technical refinement of therapies, the need for an increased understanding of how best to combine therapies with traditional cytotoxic therapies, the inability of patients to mount an effective immune response either due to disease burden or tumor induced immune suppression, the significant toxicities associated with many immunotherapies, and the lack of strongly immunogenic antigens required by many therapies. Further, antigen-non-specific immunotherapies, including cytokines such as interleukins and interferons, immuno-stimulatory agents such as CpG oligonucleotides, or BCG, antibodies targeted against receptors such as the agonistic CD40 or inhibitory CTLA-4 antibodies, and enzyme inhibitors such as those targeting cyclo-oxygenase or indolamine-2,3-dioxygenase are discussed. In addition, potential mechanisms of these therapies such as direct anti-tumor effects, reversal of immune suppression, activation of innate immunity, and antigen-non-specific T-cell activation are reviewed. We also appraise the potential of these antigen-non-specific therapies to overcome some of the previously described pitfalls of immunotherapy. Lastly, we discuss a recent series of studies from our laboratory demonstrating the importance of antigen-non-specific 'bystander activation' of memory T-lymphocytes by immunomodulatory therapies such as interleukin-2 and the antigen-non-specific anti-tumor effects of these cells.

AB - Immunotherapy in the treatment of cancer is increasing, particularly with the recent FDA approval of sipuleucel-T and ipilimumab. The efficacy of anti-tumor immunotherapies has been modest compared to their theoretical and pre-clinical promise. This review evaluates the promise and pitfalls of immunotherapy and highlight some of the obstacles to improving anti-tumor immunotherapy: the need for technical refinement of therapies, the need for an increased understanding of how best to combine therapies with traditional cytotoxic therapies, the inability of patients to mount an effective immune response either due to disease burden or tumor induced immune suppression, the significant toxicities associated with many immunotherapies, and the lack of strongly immunogenic antigens required by many therapies. Further, antigen-non-specific immunotherapies, including cytokines such as interleukins and interferons, immuno-stimulatory agents such as CpG oligonucleotides, or BCG, antibodies targeted against receptors such as the agonistic CD40 or inhibitory CTLA-4 antibodies, and enzyme inhibitors such as those targeting cyclo-oxygenase or indolamine-2,3-dioxygenase are discussed. In addition, potential mechanisms of these therapies such as direct anti-tumor effects, reversal of immune suppression, activation of innate immunity, and antigen-non-specific T-cell activation are reviewed. We also appraise the potential of these antigen-non-specific therapies to overcome some of the previously described pitfalls of immunotherapy. Lastly, we discuss a recent series of studies from our laboratory demonstrating the importance of antigen-non-specific 'bystander activation' of memory T-lymphocytes by immunomodulatory therapies such as interleukin-2 and the antigen-non-specific anti-tumor effects of these cells.

KW - Bystander T-cells

KW - Cancer

KW - Cancer vaccine

KW - Immunotherapy

KW - Tumor immunology

UR - http://www.scopus.com/inward/record.url?scp=84865327009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865327009&partnerID=8YFLogxK

U2 - 10.3109/1547691X.2012.685527

DO - 10.3109/1547691X.2012.685527

M3 - Article

C2 - 22734880

AN - SCOPUS:84865327009

VL - 9

SP - 248

EP - 258

JO - Journal of Immunotoxicology

JF - Journal of Immunotoxicology

SN - 1547-691X

IS - 3

ER -